September 22, 2017

Temptime VP global customer development Christopher Caulfield spoke with Drug Store News about how the company’s tools helps pharmacies deliver value to patients and the healthcare system. 

September 20, 2017
In order to realize the estimated $11.4 billion in savings, the Centers for Medicare and Medicaid Services would need to revise the way it currently reimburses for biosimilar drugs.
September 14, 2017

Mvasi, a biosimilar of Avastin, is indicated to treat five types of cancer. 

September 12, 2017
Recently, patient advocates and regulators have begun acknowledging a need for something to be done about increasing costs of specialty drugs — both for manufacturers and patients. 
September 12, 2017
Focus Rx offers home infusion and specialty prescription management services, and its acquisition will strengthen Diplomat’s ability to deliver solutions for increasing infusion therapy demand, the company said.
September 11, 2017

Kåre Schultz Schultz has had a nearly 30-year career in the pharmaceutical and healthcare industries, including a long stint at Novo Nordisk, where he eventually became COO. 

September 8, 2017
The approval means that Admelog has met all requirements for the regulatory agency, pending any patent issues that have not yet been resolved. 
September 7, 2017

With the acquisition, the company said it would expand the scope of Value Specialty Pharmacy’s business while retaining the current leadership and employees of Restore Rx — and its prime location near FedEx's Memphis hub. 

September 7, 2017

According to CDC data, when taken consistently, PrEP has been shown to reduce the risk of HIV infection in people who are at high risk by more than 90%.

September 5, 2017

Among the potential treatments Gilead will acquire is Kite’s most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), a cancer-fighting therapy expected to be the first to market to treat refractory aggressive non-Hodgkin lymphoma, with a Food and Drug Administration decision date of Nov. 29.

September 5, 2017

J.D. Power’s 2017 U.S. Pharmacy Study is showing a drop in overall customer satisfaction for an industry that typically ranks among the highest-scoring ones assessed by the market research company.

August 30, 2017

The FDA approved Novartis' Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia.

August 25, 2017

The accreditation applies to all of Supervalu’s 181 banner pharmacies that now have access to the specialty pharmacy offering, the company said.

August 23, 2017

The disease management accreditation was given for a number of Accordant’s  programs providing services to patients with rare chronic disease and other conditions on behalf of health plans, government-sponsored plans, labor groups, employers and third-party administrators

August 18, 2017

The drug is indicated to treat patients with all major genotypes of chronic hepatitis C infection with cirrhosis or with compensated cirrhosis.

August 18, 2017

The drug is indicated to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, or ALL.

August 18, 2017

WILMINGTON, Del. — AstaZeneca and Merck’s Lynzparza (olaparib) tablets were approved by the Food and Drug Administration, as well as given an expanded indication by the regulatory agency.

August 17, 2017

Looking forward, several trends will shape what pharmacy looks like in 10 years, including the continuation of value-based care, a focus on providing wellness resources rather than sick care and many others. 

August 16, 2017

The Centers for Disease Control and Prevention estimate that more than 1,000 Americans are treated in emergency departments for misusing prescription opioids daily.

August 14, 2017 includes information and testimonials about how DIR fees are imposed, as well as an online petition and contact information for elected officials.

August 10, 2017

In clinical trials, 33% of patients treated with Radicava showed a lower rate of decline in the loss of physical function, compared with those on a placebo.

August 10, 2017

Mylan has invested $250 million in expanding its antiretroviral production capabilities, enabling it to produce 4 billion antiretroviral tablets and capsules each year, the company said.

August 8, 2017

As it named a new president, Diplomat reported Q2 results that showed increased revenue, but highlighted the margin pressure it’s seeing as the result of DIR fees. 

August 4, 2017

Vyxeos combines two commonly used chemotherapies into a single formulation to treat patients with certain types of high-risk acute myeloid leukemia.